3/26
06:17 pm
cort
3 Reasons to Sell CORT and 1 Stock to Buy Instead [Yahoo! Finance]
Medium
Report
3 Reasons to Sell CORT and 1 Stock to Buy Instead [Yahoo! Finance]
3/17
12:28 pm
cort
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Corcept Therapeutics Incorporated - CORT
Low
Report
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Corcept Therapeutics Incorporated - CORT
3/11
12:19 pm
cort
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Corcept Therapeutics Incorporated - CORT
Low
Report
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Corcept Therapeutics Incorporated - CORT
3/10
08:16 am
cort
Corcept Therapeutics Initiates MOMENTUM Trial to Determine Prevalence of Hypercortisolism in Patients with Resistant Hypertension [Yahoo! Finance]
Low
Report
Corcept Therapeutics Initiates MOMENTUM Trial to Determine Prevalence of Hypercortisolism in Patients with Resistant Hypertension [Yahoo! Finance]
3/10
08:00 am
cort
Corcept Therapeutics Initiates MOMENTUM Trial to Determine Prevalence of Hypercortisolism in Patients with Resistant Hypertension
Medium
Report
Corcept Therapeutics Initiates MOMENTUM Trial to Determine Prevalence of Hypercortisolism in Patients with Resistant Hypertension
3/7
12:38 pm
cort
Corcept Shares Rise More Than 55% in 6 Months: Here's Why [Yahoo! Finance]
Low
Report
Corcept Shares Rise More Than 55% in 6 Months: Here's Why [Yahoo! Finance]
3/4
06:56 am
cort
Corcept Therapeutics Full Year 2024 Earnings: Misses Expectations [Yahoo! Finance]
Medium
Report
Corcept Therapeutics Full Year 2024 Earnings: Misses Expectations [Yahoo! Finance]
3/4
06:50 am
cort
Q4 Earnings Outperformers: Corcept (NASDAQ:CORT) And The Rest Of The Branded Pharmaceuticals Stocks [Yahoo! Finance]
Medium
Report
Q4 Earnings Outperformers: Corcept (NASDAQ:CORT) And The Rest Of The Branded Pharmaceuticals Stocks [Yahoo! Finance]
3/3
04:05 pm
cort
FDA Files Corcept’s New Drug Application for Relacorilant as Treatment for Patients With Hypercortisolism
Medium
Report
FDA Files Corcept’s New Drug Application for Relacorilant as Treatment for Patients With Hypercortisolism
3/3
01:25 pm
cort
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Corcept Therapeutics Incorporated - CORT
Low
Report
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Corcept Therapeutics Incorporated - CORT
2/28
11:04 pm
cort
Corcept Therapeutics Incorporated (NASDAQ: CORT) was downgraded by analysts at StockNews.com from a "buy" rating to a "hold" rating.
Medium
Report
Corcept Therapeutics Incorporated (NASDAQ: CORT) was downgraded by analysts at StockNews.com from a "buy" rating to a "hold" rating.
2/27
08:49 am
cort
Corcept Therapeutics Incorporated (NASDAQ: CORT) had its price target raised by analysts at Piper Sandler from $67.00 to $78.00. They now have an "overweight" rating on the stock.
Low
Report
Corcept Therapeutics Incorporated (NASDAQ: CORT) had its price target raised by analysts at Piper Sandler from $67.00 to $78.00. They now have an "overweight" rating on the stock.
2/27
08:08 am
cort
Corcept Therapeutics Incorporated (NASDAQ: CORT) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $115.00 price target on the stock.
Medium
Report
Corcept Therapeutics Incorporated (NASDAQ: CORT) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $115.00 price target on the stock.
2/27
02:40 am
cort
Corcept Therapeutics Inc (CORT) Q4 2024 Earnings Call Highlights: Strong Revenue Growth and ... [Yahoo! Finance]
Medium
Report
Corcept Therapeutics Inc (CORT) Q4 2024 Earnings Call Highlights: Strong Revenue Growth and ... [Yahoo! Finance]
2/26
05:17 pm
cort
Corcept (NASDAQ:CORT) Reports Sales Below Analyst Estimates In Q4 Earnings [Yahoo! Finance]
Medium
Report
Corcept (NASDAQ:CORT) Reports Sales Below Analyst Estimates In Q4 Earnings [Yahoo! Finance]
2/26
04:36 pm
cort
Corcept Therapeutics Announces Fourth Quarter and Full-Year 2024 Audited Financial Results and Provides Corporate Update [Yahoo! Finance]
Medium
Report
Corcept Therapeutics Announces Fourth Quarter and Full-Year 2024 Audited Financial Results and Provides Corporate Update [Yahoo! Finance]
2/26
04:05 pm
cort
Corcept Therapeutics Announces Fourth Quarter and Full-Year 2024 Audited Financial Results and Provides Corporate Update
Low
Report
Corcept Therapeutics Announces Fourth Quarter and Full-Year 2024 Audited Financial Results and Provides Corporate Update
2/12
04:46 pm
cort
Corcept Therapeutics to Announce Fourth Quarter and Full-Year 2024 Financial Results, Provide Corporate Update and Host Conference Call [Yahoo! Finance]
Medium
Report
Corcept Therapeutics to Announce Fourth Quarter and Full-Year 2024 Financial Results, Provide Corporate Update and Host Conference Call [Yahoo! Finance]
2/12
04:05 pm
cort
Corcept Therapeutics to Announce Fourth Quarter and Full-Year 2024 Financial Results, Provide Corporate Update and Host Conference Call
Medium
Report
Corcept Therapeutics to Announce Fourth Quarter and Full-Year 2024 Financial Results, Provide Corporate Update and Host Conference Call
2/7
08:23 am
cort
Corcept Therapeutics Incorporated (NASDAQ: CORT) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $80.00 price target on the stock.
Low
Report
Corcept Therapeutics Incorporated (NASDAQ: CORT) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $80.00 price target on the stock.
1/31
03:03 pm
cort
Corcept (CORT) Soars 13.6%: Is Further Upside Left in the Stock? [Yahoo! Finance]
Low
Report
Corcept (CORT) Soars 13.6%: Is Further Upside Left in the Stock? [Yahoo! Finance]
1/30
01:19 pm
cort
Corcept Therapeutics Incorporated (NASDAQ: CORT) had its price target raised by analysts at Canaccord Genuity Group Inc. from $78.00 to $130.00. They now have a "buy" rating on the stock.
Low
Report
Corcept Therapeutics Incorporated (NASDAQ: CORT) had its price target raised by analysts at Canaccord Genuity Group Inc. from $78.00 to $130.00. They now have a "buy" rating on the stock.
1/24
11:00 am
cort
Kuehn Law Encourages Investors of Corcept Therapeutics Inc. to Contact Law Firm
Low
Report
Kuehn Law Encourages Investors of Corcept Therapeutics Inc. to Contact Law Firm
1/23
06:06 pm
cort
Quality U.S. growth stocks that could outperform the S&P 500 [Globe and Mail, The (Toronto, Canada)]
Medium
Report
Quality U.S. growth stocks that could outperform the S&P 500 [Globe and Mail, The (Toronto, Canada)]
12/31
03:34 pm
cort
Corcept Submits Application for Another Cushing's Syndrome Drug [Yahoo! Finance]
Low
Report
Corcept Submits Application for Another Cushing's Syndrome Drug [Yahoo! Finance]